New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
08:11 EDTCGIXCancer Genetics launches CALR mutation analysis test
Cancer Genetics has launched a genetic diagnostic test for detecting mutations in the calreticulin gene. This test helps physicians identify patients with certain types of myeloproliferative neoplasms, which are blood cancers that have the potential to evolve into acute leukemia. CGI is one of the first laboratories in the U.S. to offer this test under both CLIA and NY-State Approvals. Patients with the CALR mutation are understood to have more favorable disease outcomes as well as longer overall survival in comparison to patients who possess other biomarkers. Therefore, the results of the test could have implications in predicting a patient's outlook.
News For CGIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
07:32 EDTCGIXCancer Genetics to receive $530,000 through NJ Technology Business Tax Program
Cancer Genetics announced that it has received preliminary approval for a $570,000 tax credit from the New Jersey Technology Business Tax Certificate Transfer Program for the year 2014. The company anticipates that it will be able to transfer this credit and receive approximately $530,000 in cash in mid-December.
December 8, 2014
07:37 EDTCGIXCancer Genetics announces launch of sequencing based panel for CLL
Cancer Genetics announced it has been licensed by the Clinical Laboratory Improvement Amendments to perform Focus::CLL, the company's unique next-generation sequencing-based panel for chronic lymphocytic leukemia and small lymphocytic lymphoma. The panel assesses seven genes with clinical relevance for prognosis, disease management, and treatment selection. The targeted NGS panel was designed to offer actionable and immediately relevant information for clinicians. With an analytical sensitivity of 5%, the test is able to detect biomarker mutations and aberrations that are present at very low levels and which may be missed by other, less sensitive methodologies. Improved sensitivity can lead to enhanced diagnostic and prognostic capabilities for this disease and improved patient outcomes.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use